FinBERT, a financial-language model, scores this headline as positive (95% confidence). That is the news tone only — not the full stock rating.
Stocks › SMMT
Summit Therapeutics Inc. (SMMT) stock analysis
WEAK BUY 16% confidence · analysed Oct 30, 2026
On Oct 30, 2026, our model rated Summit Therapeutics Inc. (SMMT) WEAK BUY with 16% confidence at a price of $16.20. That means the signals lean positive, but they are mixed, so conviction is low.
SectorHealthcare
IndustryBiotechnology
Market cap12.92B
Analysed price$16.20
Technical picture
The 14-day RSI is 42. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is about normal (0.8x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $29.23 and the swing low is $12.07; traders often treat these as resistance and support.
Fundamentals
The company reports a profit margin of 0.0%.
In its latest quarter it earned $-0.21 per share, which matched the $-0.21 analysts expected.
Wall Street's average rating is 1.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $30.30.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $15.88, a target of $16.94 (+6.7%) and a stop-loss at $14.18 (-10.7%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 2, 2026 whatever the price does.
Entry$15.88
Target$16.94
Stop-loss$14.18
Reassess byNov 2, 2026
Research notes
SMMT’s bull case centers on ivonescimab’s expanding oncology opportunity: positive Phase 3 HARMONi-GI1 biliary-tract-cancer data showed a 2.8-month overall-survival benefit, while several analysts retain Buy ratings and targets of $30–$40. The bear case is clinical and commercial execution risk—ivonescimab still faces regulatory hurdles, Summit has substantial R&D spending with limited revenue, and Bernstein remains skeptical with an $11.90 target. The major recent catalyst is AstraZeneca’s planned $2 billion strategic equity investment, alongside the HARMONi-GI1 readout and additional pipeline updates. Shares recently moved above their 200-day moving average near $16.19, but remain well below the 52-week high of $29.23.
The model's one-paragraph read
Leans BUY — composite score +0.16 (WEAK BUY). Technicals: RSI 41.51, MACD bearish, price above SMA50. Fundamentals: margin 0.0%. Financial results: last EPS surprise +0.0%, next earnings 2026-11-03. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Memory: 1 prior look(s). Internet research: SMMT’s **bull case** centers on ivonescimab’s expanding oncology opportunity: positive Phase 3 HARMONi-GI1 biliary-tract-cancer data showed a 2.8-month overall-survival benefit, while several analysts retain Buy ratings and targets of $30–$40. The **bear case** is clinical and commercial execution risk—ivonescimab still faces regulatory hurdles, Summit has substantial R&D spending with limited revenue, and Bernstein remains skeptical with an $11.90 target. The major recent catalyst is AstraZeneca’s planned **$2 billion strategic equity investment**, alongside the HARMONi-GI1 readout and additional pipeline updates. Shares recently moved above their 200-day moving average near $16.19, but remain well below the 52-week high of $29.23. Suggested levels: entry $15.88, target $16.94, stop-loss $14.18, exit by 2026-11-02 (exit before next earnings (2026-11-03) -- this signal doesn't price in that report).
Past ratings for SMMT
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 30, 2026 | WEAK BUY | 16% | $16.20 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on SMMT
Oct 30, 2026 · AstraZeneca Q3 revenue up 7% as cancer drugs offset Farxiga drop
- Oct 30, 2026: AstraZeneca shares gain after Q3 profit beats forecasts, outlook unchanged (Investing.com)
- Oct 30, 2026: AstraZeneca Q3 revenue up 7% as cancer drugs offset Farxiga drop (Investing.com)
Other Healthcare stocks we cover
SNN · STE · STOK · SUPN · TAK · TCMD · TKNO · UNH · UTHR · VSTM · WAT · ZBH
Frequently asked questions
Is SMMT a buy right now?
As of Oct 30, 2026, our automated model rates Summit Therapeutics Inc. (SMMT) WEAK BUY with 16% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for SMMT?
The model's most recent plan targets $16.94 with a stop-loss at $14.18, from an entry near $15.88.
When does Summit Therapeutics Inc. report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.